Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Dimitra Stefanou"'
Autor:
Stefania Kokkali, Emmanouil Saloustros, Dimitra Stefanou, Paris Makrantonakis, Nikolaos Kentepozidis, Ioannis Boukovinas, Nikolaos Xenidis, Panagiotis Katsaounis, Alexandros Ardavanis, Nikolaos Ziras, Athina Christopoulou, George Rigas, Kostas Kalbakis, Nikolaos Vardakis, Christos Emmanouilides, Ilias Athanasiadis, Athanassios Anagnostopoulos, Dora Hatzidaki, Efthimios Prinarakis, Foteini Simopoulou, Athanasios Kotsakis, Vassilis Georgoulias
Publikováno v:
Current Oncology, Vol 29, Iss 2, Pp 1237-1251 (2022)
Front-line bevacizumab (BEV) in combination with taxanes offers benefit in progression-free survival (PFS) in metastatic breast cancer (mBC). The medical records of mBC patients, treated with front-line BEV-based chemotherapy, were retrospectively re
Externí odkaz:
https://doaj.org/article/c982903354104203bb48bb3d0972f59f
Autor:
Alexandros Pergaris, Dimitra Stefanou, Panagiota Keramari, Stylianos Sousouris, Nikolaos Kavantzas, Helen Gogas, Panagiota Mikou
Publikováno v:
Diagnostics, Vol 11, Iss 12, p 2223 (2021)
The International System for Reporting Serous Fluid Cytopathology (TIS) classifies serous effusions into five categories: non-diagnostic (ND), negative for malignancy (NFM), atypia of unknown significance (AUS), suspicious for malignancy (SFM) and ma
Externí odkaz:
https://doaj.org/article/14d8776bcbb447e286580aeb512cbaef
Autor:
Christina Papanikolaou, Vasiliki Rapti, Dimitris Stellas, Dimitra Stefanou, Konstantinos Syrigos, George Pavlakis, Vassilis Souliotis
Publikováno v:
Vaccines. 10(10)
COVID-19 is an infectious disease caused by the SARS-CoV-2 coronavirus and characterized by an extremely variable disease course, ranging from asymptomatic cases to severe illness. Although all individuals may be infected by SARS-CoV-2, some people,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db19f70046dd24d9c8c013e22dfbc8c4
https://pubmed.ncbi.nlm.nih.gov/36298629
https://pubmed.ncbi.nlm.nih.gov/36298629
Autor:
Aristeidis E. Boukouris, Maria Theochari, Dimitra Stefanou, Alexandros Papalambros, Evangelos Felekouras, Helen Gogas, Dimitrios C. Ziogas
Publikováno v:
Critical reviews in oncology/hematology. 173
The long-term remissions induced by immune-checkpoint inhibitors (ICIs) in many types of cancers have opened up the possibility of a broader use of immunotherapy in less immunogenic but genetically heterogeneous tumours. Regarding metastatic colorect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48f9db7353d7ce15d34d9a30c2f039c9
https://pubmed.ncbi.nlm.nih.gov/35351582
https://pubmed.ncbi.nlm.nih.gov/35351582
Autor:
Stefania Kokkali, Emmanouil Saloustros, Dimitra Stefanou, Paris Makrantonakis, Nikolaos Kentepozidis, Ioannis Boukovinas, Nikolaos Xenidis, Panagiotis Katsaounis, Alexandros Ardavanis, Nikolaos Ziras, Athina Christopoulou, George Rigas, Kostas Kalbakis, Nikolaos Vardakis, Christos Emmanouilides, Ilias Athanasiadis, Athanassios Anagnostopoulos, Dora Hatzidaki, Efthimios Prinarakis, Foteini Simopoulou, Athanasios Kotsakis, Vassilis Georgoulias
Publikováno v:
Current Oncology; Volume 29; Issue 2; Pages: 1237-1251
Front-line bevacizumab (BEV) in combination with taxanes offers benefit in progression-free survival (PFS) in metastatic breast cancer (mBC). The medical records of mBC patients, treated with front-line BEV-based chemotherapy, were retrospectively re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d912d22acc3a1f5d3ceb8791b527d9c
https://pubmed.ncbi.nlm.nih.gov/35200604
https://pubmed.ncbi.nlm.nih.gov/35200604
Autor:
Nikolaos Kavantzas, Stylianos Sousouris, Helen Gogas, Dimitra Stefanou, Panagiota Mikou, Panagiota Keramari, Alexandros Pergaris
Publikováno v:
Diagnostics
Diagnostics; Volume 11; Issue 12; Pages: 2223
Diagnostics, Vol 11, Iss 2223, p 2223 (2021)
Diagnostics; Volume 11; Issue 12; Pages: 2223
Diagnostics, Vol 11, Iss 2223, p 2223 (2021)
The International System for Reporting Serous Fluid Cytopathology (TIS) classifies serous effusions into five categories: non-diagnostic (ND), negative for malignancy (NFM), atypia of unknown significance (AUS), suspicious for malignancy (SFM) and ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4d5571fd8773beaa9fe347840852543
http://europepmc.org/articles/PMC8700584
http://europepmc.org/articles/PMC8700584
Autor:
Lamprini Stournara, Fotini Sarropoulou, Dimitra Stefanou, Ioannis Gkiozos, Eleftheria Ntalakou, Marousa Kouvela, Nikolaos Syrigos
Publikováno v:
Lung cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::947b66ef80f579cb8e88d5a11ac35582
https://doi.org/10.1183/13993003.congress-2021.pa2311
https://doi.org/10.1183/13993003.congress-2021.pa2311
Autor:
Vasilios Ramfidis, Maria Kalliri, Andriani Charpidou, Ioannis Gkiozos, Dimitra Stefanou, Dimitra Grapsa, Konstantinos N. Syrigos
Publikováno v:
Lung cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae0543706e6476b61bd4ed53f7f1640a
https://doi.org/10.1183/13993003.congress-2021.pa2308
https://doi.org/10.1183/13993003.congress-2021.pa2308
Autor:
Ilias Kotteas, Dimitra Stefanou, Antonios Vassias, Vasileios Patriarcheas, Andriani Charpidou, I. Tourkantonis, Lamprini Stournara, Maria Mitsogianni, Konstantinos N. Syrigos, Dimitrios Vassos
Publikováno v:
Lung cancer.
Introduction: Both pembrolizumab and nivolumab have been established as valid options in second line treatment of non-small cell lung cancer (NSCLC). However, a direct comparison between them has yet not been performed. Aims and Objectives: The aim o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0bc1862b2944310b58c7bd69889378d9
https://doi.org/10.1183/13993003.congress-2020.1692
https://doi.org/10.1183/13993003.congress-2020.1692
Autor:
Evangelos Eleutherakis Papaiakovou, Dimitra Grapsa, Efstathios Kastritis, Ilias Kotteas, Ioannis Ntanassis-Stathopoulos, Dimitra Stefanou, Flora Zagouri, Konstantinos N. Syrigos, Georgios Evangelou, Meletios A. Dimopoulos
Publikováno v:
Journal of Clinical Oncology. 39:e14558-e14558
e14558 Background: Despite their efficacy in various cancer types, administration of immune checkpoint inhibitors (ICIs) may be complicated by the development of immune-related adverse events (IrAE). Nephrotoxicity represents a relatively rare but cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc88ae99899a5161c6cb808dabd7b07b
https://doi.org/10.1200/jco.2021.39.15_suppl.e14558
https://doi.org/10.1200/jco.2021.39.15_suppl.e14558